Charles Schwab Investment Management Inc Biocryst Pharmaceuticals Inc Transaction History

Charles Schwab Investment Management Inc

  • $429 Billion
  • Q1 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 1,731,803 shares of BCRX stock, worth $10.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,731,803
Previous 1,594,436 8.62%
Holding current value
$10.7 Million
Previous $9.55 Million 7.88%
% of portfolio
0.0%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 08, 2024
BUY
$4.89 - $7.65 $671,724 - $1.05 Million
137,367 Added 8.62%
1,731,803 $8.8 Million
Q4 2023

Feb 06, 2024
BUY
$4.98 - $6.77 $665,472 - $904,668
133,629 Added 9.15%
1,594,436 $9.55 Million
Q3 2023

Nov 08, 2023
BUY
$6.71 - $7.92 $130,187 - $153,663
19,402 Added 1.35%
1,460,807 $10.3 Million
Q2 2023

Aug 09, 2023
BUY
$6.96 - $8.81 $127,263 - $161,090
18,285 Added 1.28%
1,441,405 $10.1 Million
Q1 2023

May 11, 2023
BUY
$7.94 - $11.84 $21,700 - $32,358
2,733 Added 0.19%
1,423,120 $11.9 Million
Q4 2022

Feb 13, 2023
BUY
$10.5 - $14.2 $359,509 - $486,193
34,239 Added 2.47%
1,420,387 $16.3 Million
Q3 2022

Nov 14, 2022
BUY
$10.79 - $14.81 $314,474 - $431,637
29,145 Added 2.15%
1,386,148 $17.5 Million
Q2 2022

Aug 15, 2022
BUY
$7.89 - $17.88 $80,178 - $181,696
10,162 Added 0.75%
1,357,003 $14.4 Million
Q1 2022

May 13, 2022
BUY
$11.56 - $19.76 $832,620 - $1.42 Million
72,026 Added 5.65%
1,346,841 $21.9 Million
Q4 2021

Feb 11, 2022
BUY
$11.18 - $15.46 $342,655 - $473,833
30,649 Added 2.46%
1,274,815 $17.7 Million
Q3 2021

Nov 16, 2021
BUY
$14.21 - $17.65 $242,351 - $301,020
17,055 Added 1.39%
1,244,166 $17.9 Million
Q2 2021

Aug 16, 2021
BUY
$9.5 - $17.24 $191,377 - $347,299
20,145 Added 1.67%
1,227,111 $19.4 Million
Q1 2021

May 17, 2021
BUY
$7.37 - $13.61 $282,086 - $520,922
38,275 Added 3.28%
1,206,966 $12.3 Million
Q4 2020

Feb 16, 2021
SELL
$3.37 - $8.61 $4,566 - $11,666
-1,355 Reduced 0.12%
1,168,691 $8.71 Million
Q3 2020

Nov 13, 2020
BUY
$3.43 - $5.53 $830,409 - $1.34 Million
242,102 Added 26.09%
1,170,046 $4.02 Million
Q2 2020

Aug 14, 2020
BUY
$1.9 - $5.61 $130,980 - $386,736
68,937 Added 8.03%
927,944 $4.42 Million
Q1 2020

May 15, 2020
BUY
$1.6 - $4.11 $38,012 - $97,645
23,758 Added 2.84%
859,007 $1.72 Million
Q4 2019

Feb 07, 2020
BUY
$1.59 - $3.45 $412,514 - $895,078
259,443 Added 45.06%
835,249 $2.88 Million
Q3 2019

Nov 08, 2019
SELL
$2.5 - $3.73 $192,317 - $286,937
-76,927 Reduced 11.79%
575,806 $1.65 Million
Q2 2019

Aug 09, 2019
SELL
$2.91 - $9.15 $368,499 - $1.16 Million
-126,632 Reduced 16.25%
652,733 $2.47 Million
Q1 2019

May 14, 2019
BUY
$7.38 - $9.72 $1.34 Million - $1.76 Million
181,543 Added 30.37%
779,365 $6.35 Million
Q4 2018

Feb 14, 2019
SELL
$6.51 - $9.6 $117,707 - $173,577
-18,081 Reduced 2.94%
597,822 $4.83 Million
Q3 2018

Nov 13, 2018
BUY
$5.52 - $7.99 $534,573 - $773,775
96,843 Added 18.66%
615,903 $4.7 Million
Q2 2018

Aug 08, 2018
BUY
$4.6 - $6.52 $129,186 - $183,107
28,084 Added 5.72%
519,060 $2.98 Million
Q1 2018

May 07, 2018
SELL
$4.35 - $5.82 $25,299 - $33,849
-5,816 Reduced 1.17%
490,976 $2.34 Million
Q4 2017

Jan 17, 2018
BUY
$4.16 - $5.33 $735,130 - $941,885
176,714 Added 55.21%
496,792 $2.44 Million
Q3 2017

Nov 13, 2017
BUY
$4.1 - $5.97 $1.31 Million - $1.91 Million
320,078
320,078 $1.68 Million

Others Institutions Holding BCRX

# of Institutions
258
Shares Held
182M
Call Options Held
839K
Put Options Held
816K
View Full List

About BIOCRYST PHARMACEUTICALS INC

BCRX Quotes by TradingView
  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.15B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email